MTOR and chromophobe renal cell carcinoma: The combination of a tyrosine kinase inhibitor (lenvatinib 18mg) with an inhibitor of the mTOR pathway (everolimus 5mg) was approved in a phase 2 multicenter trial including 31 patients, nine of whom had chromophobe carcinoma.